Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
NCT01201356
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
4125
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
DRUG:
Fingolimod
Sponsor
Novartis Pharmaceuticals